FDA Panel Backs Donanemab: New Hope for Early Alzheimer's Treatment

Eli Lilly's Alzheimer's drug, Donanemab, has been recommended for FDA approval by an independent panel. The drug has shown promise in slowing early-stage Alzheimer's, despite risks like brain swelling. This recommendation follows a prior FDA rejection due to insufficient data. If approved, Donanemab could revolutionize Alzheimer's treatment, offering new hope for patients and their families.